HUTCHMED Initiates Development of ATTC Candidate

Summary by AI BETAClose X

HUTCHMED has initiated global clinical development for HMPL-A251, a novel Antibody-Targeted Therapy Conjugate (ATTC) targeting solid tumors expressing HER2, with the first patient dosed on December 16, 2025, in China. This first-in-human Phase I/IIa study will evaluate the safety, tolerability, and preliminary efficacy of HMPL-A251, which combines a potent PI3K/PIKK inhibitor with an anti-HER2 antibody to enhance targeted delivery and potentially reduce systemic toxicity. The development strategy includes simultaneous trials in both China and the US to expedite the process, marking the first clinical candidate from HUTCHMED's next-generation ATTC platform.

Disclaimer*

UK 100

Latest directors dealings